Compare Infosys Limited (INFY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Zoetis Inc — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Infosys Limited is the larger of the two by market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Zoetis Inc for 70 Days on average.
| INFY | ZTS | |
|---|---|---|
Market Cap | $41.74B | $30.20B |
Volume | 31,354,285 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $20.22 | $147.53 |
52-Week Low | $10.49 | $69.09 |
Typical Hold Time | 27 Days | 70 Days |
Enterprise Value | $39.48B | $37.76B |
Dividend Yield | 4.89% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro. Analyst consensus is a 'Hold' with a $11.48 price target, indicating modest upside potential from current levels.
The outlook is mixed: strong profitability and recent earnings beats support the stock, but a projected negative net cash flow in 2026 and bearish technical indicators pose risks. Investor sentiment is cautious amid weak Western IT spending concerns, though institutional holdings show confidence. Key risks include competitive pressures and macroeconomic headwinds affecting IT services demand.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
